20:08 EDT Cathie Wood’s ARK Investment bought 174K shares of Intellia Therapeutics today
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia announces long-term data from ongoing Phase 1 study of NTLA-2002
- Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
- Intellia Therapeutics price target lowered to $29 from $31 at Citi
- Intellia Therapeutics reports Q1 EPS ($1.12), consensus ($1.38)
- Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress